Zhongshan Ophthalmic Center

Company snapshot

白云山高，珠江水长，中国的南大门羊城——广州，是“ 海上丝绸之路 ”的 发祥地 ，中国第三大城市，拥有中国第二大的国际航空枢纽和便利的公共设施，是一个快速发展的现代化国际大都市。闻名遐迩的中山大学中山眼科中心就座落于这个美丽的城市。 中山眼科中心的历史渊源最早可追溯到1835年由美国传教士医师伯驾（Peter Parker）创办的眼科医局——中国最早的西医院。1953年，中山大学医学院和岭南大学医学院合并成立华南医学院，两个医学院的眼科合并为华南医学院眼科教研组；1954年，光华医学院眼科也并入华南医学院眼科教研组；1956年，随着华南医学院更名为广州医学院，眼科教研组更名为广州医学院眼科教研组；1957年，又更名为中山医学院眼科教研组。在此基础上，1965年10月，陈耀真教授、毛文书教授等创办成立了中山医学院眼科医院，这是第一间中国高等院校附属眼科医院。1983年6月，中山医学院中山眼科

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Zhongshan Ophthalmic Center. Not investment advice.

• What is Zhongshan Ophthalmic Center?

  Zhongshan Ophthalmic Center is a pharma organization headquartered in CN. Primary therapeutic focus areas include Pterygium, Open Angle Glaucoma. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTri

• Is Zhongshan Ophthalmic Center publicly traded?

  Zhongshan Ophthalmic Center appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Zhongshan Ophthalmic Center develop or market?

  We link 5 drug profile(s) where Zhongshan Ophthalmic Center is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/zhongshan-ophthalmic-center-sun-yat-sen-university#company-drugs.

• What are the latest developments for Zhongshan Ophthalmic Center?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Zhongshan Ophthalmic Center focus on?

  Zhongshan Ophthalmic Center focuses on Pterygium, Open Angle Glaucoma based on our analysis of their pipeline programs and drug development activities.